Table 2.
Trials Utilizing Mortality as an Endpoint Whose Point Estimate Favor the Active Control. Negative Risk Reduction Favors the New Intervention. Delta is Reported as Absolute Risk Reduction
| Author | Endpoint | Delta (%) | ARR (95% CI) | Consort class |
|---|---|---|---|---|
| Schulman8 | Recurrent or fatal VTE | 2.8 | 0.5 (− 0.3 to 1.5) | C |
| Motzer9 | Progression-free survival | 14.5 | 2.0 (− 3.9 to 7.7) | C |
| von Birgelen10 | Target vessel failure (includes death) | 3.6 | 0.9 (− 1.2 to 3.0) | C |
| Pilgrim11 | Death, MI, revascularization | 3.5 | 0.14 (− 2.2 to 2.0) | C |
| Büller12 | Symptomatic recurrent VTE (includes death) | 1.8 | 0.2 (− 0.5 to 1.0) | C |
| Raungaard13 | Death, MI, or revascularization | 2.5 | 0.25(− 1.3 to 1.8) | C |
| Feres14 | NACCE (includes death, myocardial infarction, stroke, or major bleeding) | 2.7 | 0.2 (− 1.5 to 1.8) | C |
| Jacobs15 | MACE (includes death, myocardial infarction, revascularization, and stroke) | 4.7 | 0.09 (− 2.1 to 2.3) | C |
| Ellis16 | Cardiac death, target-vessel myocardial infarction, or ischemia-driven target-lesion revascularization | 4.5 | 1.7 (− 0.6 to 4.0) | C |
| Smits17 | Death, MI, revascularization | 4.0 | 0.36 (− 1.4 to 2.1) | C |
| Pritchard-Jones18 | Event-free survival at 2 years after diagnosis | 10.0 | 4.1 (− 0.7 to 8.9) | C |
| Rosenfield19 | Death, stroke, or MI | 3.0 | 0.4 (− 1.2 to 2.6) | C |
| Crook20 | Survival | 8.0 | 2.1 (− 3.0 to 7.2) | C |
| Ardrehali21 | 30-day patient/graft survival | 10.0 | 2.8 (− 4.3 to 9.9) | C |
| Stone22 | Death, stroke, MI at 3 years | 4.0 | 0.7 (− 2.5 to 3.9) | C |
| Merle23 | Treatment failure, recurrence, or death or study dropout during treatment | 6.0 | 3.8 (− 0.4 to 8.0) | F |
| Christiansen24 | Death, MI, stent thrombosis, revascularization | 2.0 | 0.92 (− 0.6 to 2.3) | F |
| Paton25 | “Good HIV control” (see text, included survival) | 10.0 | 4.4 (− 2.3 to 11.0) | F |
| Kirchhhof26 | Time to persistent atrial fibrillation or death | 12.0 | 6.8 (− 1.6 to 15.3) | F |
| Johnson27 | 3-year progression free survival | 5.0 | 1.4 (− 3.1 to 6.0) | F |
| Radford28 | Progression-free survival | 7.0 | 3.8 (− 1.9 to 9.3) | F |
| Park29 | Death, MI, revascularization | 4.0 | 3.1 (− 0.8 to 6.9) | F |
| Anderson30 | Death or disability at 90 days | 3.3 | 2.1 (− 1.3 to 5.5) | F |
| Bousser31 | Fatal or non-fatal ischemic stroke, fatal or non-fatal myocardial infarction, or other vascular death | 0.55 | 0.29 (− 0.6 to 1.1) | F |
| Paul32 | MRSA infections treatment failure at day 7 including death | 15 | 10.4 (− 1.1 to 21.9) | F |
| Hussain33 | Survival | 11.6 | 4.5 (− 0.3 to 9.4) | F |
| Behringer34 (analysis #1) | Freedom from treatment failure | 6.0 | 11.8 (6.0 to 17.6) | G |
| Behringer34 (analysis #2) | Freedom from treatment failure | 6.0 | 4.0 (0.7 to 7.3) | G |
| Kaul35 | Cardiac death, target-vessel myocardial infarction, or ischemia-driven target-vessel revascularization | 4.0 | 2.7 (0.78 to 4.5) | G |
| Bwakura-Dangarembizi36 | Hospitalization or death | 3.0 | 6.0 (0.9 to 11.2) | G |
| Behringer34 (Analysis #3) | Freedom from treatment failure | 6.0 | 15.7 (9.1 to 22.4) | H |
| Jindani37 | “Unfavorable response” (see text) | 6.0 | 13.3 (6.5 to 20.0) | H |
HIV human immunodeficiency virus, MI myocardial infarction, MRSA methicillin-resistant Staphylococcus aureus, NACCE net adverse cardiac and cerebral events, MACE major adverse cardiac event, VTE venous thromboembolism